CTA or percentage of simulated subjects with free antimicrobial plasma concentrations above the MICs for potential SSI pathogens (4 h after the pre-operative dose for all antimicrobials except 2 h for cefoxitin)
| AP . | Aerobic SSI pathogensa . | Anaerobic SSI pathogensb . |
|---|---|---|
| Recommended | ||
| cefazolin 2 g plus metronidazole 500 mg | 70% | 99% |
| cefoxitin 2 g | 63% | 27% |
| Broad-spectrum alternatives | ||
| ceftriaxone 2 g plus metronidazole 500 mg | 82% | 99% |
| ertapenem 1 g | 88% | 90% |
| Non-β-lactam alternatives | ||
| gentamicin 5 mg/kg plus metronidazole 500 mg | 82% | 99% |
| gentamicin 5 mg/kg plus clindamycin 900 mg | 91% | 11% |
| levofloxacin 500 mg plus metronidazole 500 mg | 79% | 99% |
| levofloxacin 500 mg plus clindamycin 900 mg | 79% | 11% |
| AP . | Aerobic SSI pathogensa . | Anaerobic SSI pathogensb . |
|---|---|---|
| Recommended | ||
| cefazolin 2 g plus metronidazole 500 mg | 70% | 99% |
| cefoxitin 2 g | 63% | 27% |
| Broad-spectrum alternatives | ||
| ceftriaxone 2 g plus metronidazole 500 mg | 82% | 99% |
| ertapenem 1 g | 88% | 90% |
| Non-β-lactam alternatives | ||
| gentamicin 5 mg/kg plus metronidazole 500 mg | 82% | 99% |
| gentamicin 5 mg/kg plus clindamycin 900 mg | 91% | 11% |
| levofloxacin 500 mg plus metronidazole 500 mg | 79% | 99% |
| levofloxacin 500 mg plus clindamycin 900 mg | 79% | 11% |
a34.8% E. coli, 21.6% S. aureus, 10.5% P. aeruginosa, 10.1% Klebsiella spp., 10.1% Streptococcus spp., 8.4% Enterobacter spp. and 4.5% Proteus spp.
b59.9% B. fragilis and 40.1% other Bacteroides spp.
CTA or percentage of simulated subjects with free antimicrobial plasma concentrations above the MICs for potential SSI pathogens (4 h after the pre-operative dose for all antimicrobials except 2 h for cefoxitin)
| AP . | Aerobic SSI pathogensa . | Anaerobic SSI pathogensb . |
|---|---|---|
| Recommended | ||
| cefazolin 2 g plus metronidazole 500 mg | 70% | 99% |
| cefoxitin 2 g | 63% | 27% |
| Broad-spectrum alternatives | ||
| ceftriaxone 2 g plus metronidazole 500 mg | 82% | 99% |
| ertapenem 1 g | 88% | 90% |
| Non-β-lactam alternatives | ||
| gentamicin 5 mg/kg plus metronidazole 500 mg | 82% | 99% |
| gentamicin 5 mg/kg plus clindamycin 900 mg | 91% | 11% |
| levofloxacin 500 mg plus metronidazole 500 mg | 79% | 99% |
| levofloxacin 500 mg plus clindamycin 900 mg | 79% | 11% |
| AP . | Aerobic SSI pathogensa . | Anaerobic SSI pathogensb . |
|---|---|---|
| Recommended | ||
| cefazolin 2 g plus metronidazole 500 mg | 70% | 99% |
| cefoxitin 2 g | 63% | 27% |
| Broad-spectrum alternatives | ||
| ceftriaxone 2 g plus metronidazole 500 mg | 82% | 99% |
| ertapenem 1 g | 88% | 90% |
| Non-β-lactam alternatives | ||
| gentamicin 5 mg/kg plus metronidazole 500 mg | 82% | 99% |
| gentamicin 5 mg/kg plus clindamycin 900 mg | 91% | 11% |
| levofloxacin 500 mg plus metronidazole 500 mg | 79% | 99% |
| levofloxacin 500 mg plus clindamycin 900 mg | 79% | 11% |
a34.8% E. coli, 21.6% S. aureus, 10.5% P. aeruginosa, 10.1% Klebsiella spp., 10.1% Streptococcus spp., 8.4% Enterobacter spp. and 4.5% Proteus spp.
b59.9% B. fragilis and 40.1% other Bacteroides spp.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
